# Study of Latiglutenase in T1D/CD Patients

> **NCT04839575** · PHASE2 · TERMINATED · sponsor: **Entero Therapeutics** · enrollment: 13 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Latiglutenase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04839575
- **Lead sponsor:** Entero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-06
- **Primary completion:** 2022-12-19
- **Final completion:** 2022-12-19
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Covid-19 interruptions and enrollment challenges
- **Last updated:** 2024-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04839575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04839575, "Study of Latiglutenase in T1D/CD Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04839575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*